Salivary and plasma free testosterone and androstenedione levels in women using oral contraceptives containing desogestrel or levonorgestrel.
The effect of oral contraceptives (OC) containing a combination of ethinyloestradiol (EE2) and either desogestrel (Dg/EE2) or levonorgestrel (Lg/EE2) on plasma concentrations of sex hormone binding globulin (SHBG), total testosterone (T), free T, total androstenedione (A), free A and on salivary T and A concentrations have been studied. SHBG concentrations were higher in the Dg/EE2 group than in the Lg/EE2 group. Total T, measured by RIA with prior extraction and chromatography, is also higher in the Dg/EE2 group. Per cent free T was lower in the Dg/EE2 group. Plasma free T and free A concentrations were the same in both groups. However, free T and free A were significantly lower in the OC-groups than in controls. In contrast, by direct assay, no difference in total T was observed between the OC-groups. Since the per cent free T was lower in the Dg/EE2 group, it would be concluded that free T in the Dg/EE2 group is lower than in the Lg/EE2 group. Salivary free T and free A concentrations did not differ between control and OC-groups. There was good correlation between salivary and free hormone concentrations within each group. We conclude that the concentrations of androgens in saliva do not necessarily directly reflect their free concentrations in plasma.
Swinkels
L M
LM
Department of Experimental and Chemical Endocrinology, St Radboud University Hospital, Nijmegen, the Netherlands.
Meulenberg
P M
PM
Ross
H A
HA
Benraad
T J
TJ
D000293:Adolescent; D000328:Adult; D000735:Androstenedione / Q000032:analysis / Q000097:blood*; D003271:Contraceptive Agents, Female / Q000494:pharmacology / Q000627:therapeutic use; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology* / Q000627:therapeutic use; D017135:Desogestrel; D005260:Female; D005298:Fertility / Q000187:drug effects; D006801:Humans; D016912:Levonorgestrel; D008875:Middle Aged; D009644:Norgestrel / Q000494:pharmacology* / Q000627:therapeutic use; D009652:Norpregnenes / Q000494:pharmacology* / Q000627:therapeutic use; D012463:Saliva / Q000032:analysis*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000032:analysis / Q000097:blood*
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; D012738:Sex Hormone-Binding Globulin; D009644:Norgestrel; D013739:Testosterone; D000735:Androstenedione; D016912:Levonorgestrel; D017135:Desogestrel